Grifols Balance Sheet Health

Financial Health criteria checks 2/6

Grifols has a total shareholder equity of €8.0B and total debt of €9.5B, which brings its debt-to-equity ratio to 119.6%. Its total assets and total liabilities are €21.4B and €13.5B respectively. Grifols's EBIT is €735.7M making its interest coverage ratio 1.9. It has cash and short-term investments of €646.0M.

Key information

119.6%

Debt to equity ratio

€9.54b

Debt

Interest coverage ratio	1.9x
Cash	€646.05m
Equity	€7.97b
Total liabilities	€13.47b
Total assets	€21.44b

Recent financial health updates

No updates

Recent updates

Portfolio Manager Diary: Contrast The Information Obtained By The Company Management Before Investing

Jan 03

Grifols Class B: Buy The Recovery In The U.S. Plasma Business

Nov 11

Grifols S.A. goes ex-dividend tomorrow

Oct 29

Financial Position Analysis

Short Term Liabilities: GRFS's short term assets (€6.5B) exceed its short term liabilities (€2.3B).

Long Term Liabilities: GRFS's short term assets (€6.5B) do not cover its long term liabilities (€11.2B).

Debt to Equity History and Analysis

Debt Level: GRFS's net debt to equity ratio (111.5%) is considered high.

Reducing Debt: GRFS's debt to equity ratio has reduced from 133.8% to 119.6% over the past 5 years.

Debt Coverage: GRFS's debt is not well covered by operating cash flow (2.2%).

Interest Coverage: GRFS's interest payments on its debt are not well covered by EBIT (1.9x coverage).

Grifols Balance Sheet Health

Financial Health criteria checks 2/6

Key information

Recent financial health updates

Recent updates

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols: Q4 Was Positive, Still Too Many Question Marks

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols: I've Read The Short-Seller Report, And I Mostly Disagree

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Grifols inks 15-year deal with Canada for plasma-derived therapies

Grifols: Every Cloud Has A Silver Lining

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols: Long Only

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021

Grifols Takes Another Step in the Fight Against Alzheimer's, Partners with Ace to Open First Ambar® Center in Barcelona

Grifols shares rise after Andorra Development and Investment deal

Grifols Launches Patient Point-Of-Care System for Monitoring Infliximab in Europe

Grifols, S.A. (BME:GRF) acquired remaining 56% stake in GigaGen, Inc. for $80 million

Grifols, S.A. (BME:GRF) acquired 25 U.S. Based Plasma Donation Centers of BPL Plasma, Inc for $370 million.

Grifols, S.A.(BME:GRF.P) dropped from S&P Global BMI Index

Grifols Begins Clinical Trial of A New Treatment That Would Provide Immediate Immunity Against Covid-19

Portfolio Manager Diary: Contrast The Information Obtained By The Company Management Before Investing

Grifols, S.A. Announces Board Appointments

Grifols, S.A. (BME:GRF) completed the acquisition of remaining 52.4% stake in Alkahest, Inc.

Grifols, S.A. Executes Binding Master Joint Venture Agreement with National Service Projects Organization

B. Braun Melsungen AG and Grifols Forms Strategic Alliance to Offer Integrated Solutions for Safe Automated Drug Preparation and Administration

Grifols Class B: Buy The Recovery In The U.S. Plasma Business

Grifols, S.A. (BME:GRF) acquired remaining 49% stake in Goetech LLC for $60.2 million.

Grifols S.A. goes ex-dividend tomorrow

Grifols' anti-SARS-CoV-2 Hyperimmune Globulin Begins Clinical Trial in Patients with Covid-19

Grifols, S.A. (BME:GRF) agreed to acquire 53.4% stake in Green Cross Biotherapeutics Inc. from Green Cross North America Inc. for approximately KRW 190 billion.

Grifols, S.A. to Report Q3, 2020 Results on Nov 05, 2020

Grifols, S.A. (BME:GRF) completed the acquisition of Plasma Fractionation Facility in Montreal and Plasma Collection Centers in US from Green Cross Corporation (KOSE:A006280).

Grifols, S.A. (BME:GRF) agreed to acquire remaining 52.4% stake in Alkahest, Inc. for approximately $150 million.

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies